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Objective: Muscle wasting (‘rheumatoid cachexia’) is evident in most rheumatoid arthritis (RA) 
patients, including those with well-controlled disease, and contributes substantially to the reductions 
in strength and physical function that are characteristic of this disease. The aim of this randomized 
controlled trial was to investigate the efficacy of oral creatine (Cr) supplementation on improving 
muscle mass, strength and function in stable RA patients. 
Method: Forty RA patients were randomized to 12 weeks supplementation of Cr or placebo, in a 
double-blind fashion. Body composition (by whole-body dual-energy X-ray absorptiometry, DXA, and 
bioelectrical impedance spectroscopy, BIS), strength and objectively-assessed physical function 
measures were taken at baseline, week 12, and week 24 (i.e. after 12 weeks of treatment withdrawal).  
Data was analyzed by ANCOVA. 
Results: Cr supplementation increased appendicular lean mass (ALM; a surrogate DXA measure of 
muscle mass) by (mean±SE) 0.52±0.13kg (P=0.004 vs placebo), and total LM by 0.60±0.37kg 
(P=0.158 vs placebo). The increment in LM by DXA corresponded with the elevation in intracellular 
water (ICW) estimated by BIS (0.64±0.22 L, P=0.035 vs placebo).  However, the observed increases 
in ALM, total LM and ICW were not accompanied by improvements in isometric knee extensor 
strength (P=0.408), hand-grip strength (P=0.833), or objectively assessed function (30s sit-to-stand, 
50’ walk, 8’ up-&-go, estimated VO2max; P’s=0.335-0.764) 
Conclusion: Twelve weeks of Cr supplementation improved muscle mass, but not strength or 
objectively-measured physical function in RA patients. As no adverse treatment-related effects 
occurred, Cr supplementation appears to be a safe and acceptable adjunct treatment for attenuating 
muscle loss in RA patients.  This treatment may be especially suitable for patients with severe 
rheumatoid cachexia. 
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Supplement: Patients with RA usually experience substantial loss of lean mass (LM) (known as 
‘rheumatoid cachexia’ (RC) (1). This loss of LM is a major contributor to the decreased strength and 
impaired physical function (2,3) that characterizes RA.  
 
Unfortunately, current pharmacologic treatments for RA do not ameliorate this LM loss, nor fully 
restore physical function (3). Whilst exercise (specifically, progressive resistance training (PRT)) has 
been shown to be highly effective in restoring both LM and function in RA patients (2), the lack of 
adherence to sufficiently intense training means this form of therapy is unlikely to be widely adopted 
(4). Anabolic nutritional supplementation offers a potential adjunct treatment intervention for 
improving LM and function that should be widely acceptable. Indeed, our group (5) has previously 
demonstrated that daily oral protein supplementation for 12 weeks improved LM and some measures 
of objectively-assessed physical function in RA patients.  
 
Creatine (Cr), a combination of essential amino acids, is a popular dietary supplement generally shown 
to have greater benefits on both LM and physical function than generic protein. To date, only one study 
(6) has investigated the efficacy of oral Cr supplementation in RA patients. In this uncontrolled trial, 
twelve patients underwent three weeks of supplementation, and although strength increased, body 
composition changes were not investigated. 
 
To further investigate the efficacy of Cr supplementation in improving LM, strength and function in RA 
patients, we recruited 40 patients with stable RA disease (i.e. no change in medications in the preceding 
3 months) from outpatient clinics. Participants were randomised to receive either supplementary Cr or 
placebo drinks for 12 weeks, with the groups matched for age and sex. Both the principle researcher 
(TW) and participants were blinded to supplement assignment. 
 
In accordance with manufacture recommendations, and previous strategies (e.g. 6,7), the Cr group 
received 20 g of Cr monohydrate (4 x 5 g/day) for a 5-day ‘loading phase’ followed by 3 g/day for the 
remainder of the 12 week supplementation period (‘maintenance dose’). The Cr was mixed with a 
mango-flavoured drink powder to improve taste. The placebo group received only the mango-flavoured 
drink powder. The appearance of the different treatment packets were indistinguishable, as were the 
flavouring and colouring of the drinks.  
 
The flow of patients through the study is shown in Figure 1. Subjects’ baseline demographics are 
presented in Table 1, and the effects of Cr supplementation on body composition in Table 2. Twelve 
weeks of Cr supplementation resulted in a significant increase in ALM of 0.52 (±0.13) kg in the Cr group, 
with no change in the placebo group (0.05 (±0.13) kg; between-group P = .004, effect size (η2) = .23 
(medium)). Similarly, total LM increased by 0.60 (±0.37) kg) following Cr supplementation, with no 
change in the placebo group over the same period (-0.06 (±0.29) kg), albeit the between-group change 
was not significant (P = .158, η2 = .06 (small)). In the Cr group there was an increase in intra-cellular 
water (ICW) from baseline to week 12 (0.64 ±0.22 L, P = .035, η2 = .13 (medium)). 
 
After 12 weeks of cessation of Cr supplementation (week 24), there was a regression towards baseline 
for ALM and total LM, which further supports a Cr treatment effect. No changes in FM or body fat % 
were observed at any time point for either group. 
 
In contrast to the effects on muscle mass, Cr supplementation had no effect on objectively-assessed 
physical function (Table 3).  
 
The magnitude of LM increase we observed is comparable to that seen previously in older men and 
women following Cr supplementation. The body composition changes are also similar to those we 
previously observed following 12 weeks of protein supplementation in RA patients (i.e. increases of 0.40 
kg in ALM and 0.73 kg in total LM, whilst FM remained unchanged (5)). These results, together with 
the response to PRT (2), and the finding that muscle quality (i.e. maximal force exerted per unit muscle) 
is not impaired in RA patients (8), further emphasise that RA patients are not, as once believed (9), 
resistant to muscle anabolic stimuli. 
 
Interestingly, at week 24, despite the losses due to withdrawal of Cr, ALM and total LM were still 0.40 
kg and 0.21 kg, respectively, above baseline values, suggesting some longer term retention of muscle 
mass following Cr supplementation.  
 
The lack of a Cr-induced improvement in either strength or function that we observed in this study 
contrasts with the 14% gain in composite strength reported by Willer et al. (6) following short-term Cr 
supplementation in RA patients. However, the reported effects of Cr supplementation on measures of 
strength and function in older individuals are equivocal. Additionally, responsiveness to Cr 
supplementation is reported to vary, with only ~70–75% of individuals, irrespective of age, deemed to 
be ‘responders’ (7). Consistent with this estimation, 80% of our participants ‘responded’, when 
‘response’ is defined by increased ALM (≥0.24 kg).  
 
Although the lack of effects on strength and physical function are disappointing, the increase in LM we 
demonstrated suggests that Cr supplementation may be beneficial in patients with severe RC, since a 
marked loss of LM both impairs the body’s ability to fight infection due to limited expendable protein 
reserve for immune cell production, and increases the risk of mortality. The lack of efficacy 
demonstrated on physical function in this study further emphasises that sustained PRT (2) should be 
performed by RA patients wishing to substantially increase LM, and, subsequently, restore their 
strength and physical functioning.  
 
 
The importance of this study: In patients with RA, 12 weeks of oral Cr supplementation had 
beneficial effects on muscle mass, but not on strength or objectively-assessed physical function. Given 
compliance to Cr was high, and no adverse treatment-related effects were observed, Cr may offer an 
acceptable, safe, low-cost, and reasonably effective means for RA patients with severe RC to help restore 
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Table 1. Baseline demographics of rheumatoid arthritis patients who underwent 
12 weeks of oral creatine or placebo supplementation 
 
 Creatine (n = 15) Placebo (n = 20) P 
 Age (years) 63.0 (±10.0) 57.2 (±10.4) .104 
 Sex (female) (%) 10 (67) 14 (70) .833 
 Disease duration (months) 112.4 (±82.8) 141.4 (±160.1) .493 
 Rheumatoid factor +, n (%) 8 (53) 13 (65) .376 
 Height (cm) 165.1 (±7.9) 166.1 (±9.1) .734 
 BM (kg) 67.31 (±10.29) 76.73 (±18.99) .092# 
 BMI (kg/m2) 24.7 (±3.6) 27.8 (±6.6) .113 
 ALM (kg) 18.4 (±4.2) 20.6 (±5.7) .227 
 Total LM (kg) 45.9 (±8.5) 50.1 (±12.4) .274 
 Total FM (kg) 19.8 (±7.2) 24.9 (±10.5) .113 
 DAS28 2.8 (±0.8) 2.6 (±0.9) .608 
 
Strength and physical function measures 
 IKES (N) 348 (±156) 417 (±127) .159 
 HGS (N) 236.6 (±92.8) 237.9 (±99.8) .969 
 STS-30 (reps) 11.7 (±4.0) 13.2 (±2.9) .206 
 8’UG (secs) 8.2 (±3.3) 6.6 (±1.7) .119 
 50’W (secs) 11.0 (±4.0) 9.8 (±2.2) .300 
 VO2max (L/min) 1.8 (±0.4) 1.7 (±0.5) .918 
 MDHAQ 0.5 (±0.5) 0.5 (±0.4) .917 
 
BM = body mass; BMI = body mass index; ALM = appendicular lean mass; FM = fat mass; DAS28 = 
disease activity score in 28 joints; NSAIDS = non-steroidal anti-inflammatory drugs; DMARDs = disease 
modifying anti-rheumatic drugs; IKES = isometric knee extensor strength; HGS = handgrip strength; 
STS-30 = sit-to- stand in 30 second test; 8’UG = 8-foot up and go; 50’W = 50-foot walk; VO2max = 
estimated V02max from Siconolfi step test; MDHAQ = Multi-dimensional Health Assessment 
Questionnaire. a = current corticosteroid use, range 2.5–5.0 mg. Unless stated, data presented as mean 
(±SD). * P < .05; # P = .05–.10. 
  
Table 2. Changes in body composition in rheumatoid arthritis patients following 12 weeks oral creatine supplementation 
and 12 weeks withdrawal from supplementation. 
 
  Creatine (n = 15) Placebo (n = 20) Differences between-group for ∆ 
  Mean Mean Mean (CI) P η2 
 ALM (kg) Δ B–12 +0.52 (±0.13) +0.01 (±0.11) 0.52 (0.18–0.86) .004* .23 
 Δ B–24 +0.40 (±0.18) +0.15 (±0.15) 0.25 (-0.23–0.73) .293 .03 
 Total LM (kg) Δ B–12 +0.60 (±0.37) -0.06 (±0.29) 0.65 (-0.27–1.57) .158 .06 
 Δ B–24 +0.21 (±0.37) +0.19 (±0.32) 0.01 (-0.99–1.01) .977 .00 
 BM (kg) Δ B–12 +1.10 (±0.58) +0.11 (±0.46) 0.99 (-0.54–2.52) .195 .06 
 Δ B–24 +0.61 (±0.70) +0.92 (±0.55) -0.31 (-2.15–1.53) .736 .00 
 Total FM (kg) Δ B–12 +0.41 (±0.45) +0.18 (±0.37) 0.23 (-0.94–1.40) .693 .01 
 Δ B–24 +0.65 (±0.52) +0.48 (±0.45) 0.17 (-1.26–1.60) .810 .00 
 Body fat (%) Δ B–12 +0.1 (±0.4) +0.5 (±0.3) -0.3 (-1.4–0.8) .595 .01 
 Δ B–24 +0.3 (±0.5) +0.6 (±0.4) -0.3 (-1.6–1.0) .608 .01 
 
Water compartments 
 TBW (L) Δ B–12 +1.08 (±0.27) -0.01 (±0.23) 1.07 (0.34–1.8) .005* .22 
 Δ B–24 +0.42 (±0.31) -0.11 (±0.27) 0.53 (-0.32–1.37) .213 .05 
 ICW (L) Δ B–12 +0.64 (±0.22) -0.01 (±0.19) 0.65 (-0.05–1.24) .035* .13 
 Δ B–24 +0.12 (±0.24) -0.10 (±0.20) 0.22 (-0.41–0.85) .481 .02 
 ECW (L) Δ B–12 +0.44 (±0.11) 0.0 (±0.09) 0.44 (-0.15–0.73) .004* .23 
 Δ B–24 +0.36 (±0.12) +0.03 (±0.11) 0.36 (0.03–0.68) .035* .13 
 
ALM = appendicular lean mass; BM = body mass (scales); FM = fat mass; TBW = total body water; ICW = intracellular water; ECW = extracellular water. 
Changes (Δ) between time points (B = baseline, 12 = week 12 (immediately post-supplementation); 24 = week 24 (12 weeks post-supplementation)) are 
presented as the adjusted mean (±SE) from ANCOVA. The between-group difference for each Δ is displayed with 95% confidence interval (CI) along and effect 
size, eta squared (η2): small = .01; medium = .08; large = .26; very large = .50. * P < .05.
Table 3. Changes in strength and objective physical function measures in rheumatoid arthritis patients following 12 weeks 
oral creatine supplementation and 12 weeks withdrawal from supplementation. 
 
  Creatine (n = 15) Placebo (n = 20) Differences between-group for ∆ 
  Mean  Mean  Mean (CI) P η2 
Strength measures 
 IKES (N) Δ B–12 +26 (±12) +13 (±10) 13 (-19–45) .408 .02 
 Δ B–24 +34.3 (±13.7) +0.7 (±11.8) 33.6 (-3.6–70.9) .075# .10 
 HGS (N) Δ B–12 +11.0 (±6.8) +9.1 (±5.9) 1.9 (-16.3–20.1) .833 .00 
 Δ B–24 +9.5 (±6.0) +9.2 (±5.2) 0.3 (-15.9–16.6) .969 .00 
 
Objective physical function measures 
 STS-30 (reps) Δ B–12 +2.0 (±0.7) +1.8 (±0.5) 0.2 (-1.6–1.9) .764 .02 
 Δ B–24 +2.1 (±0.7) +2.3 (±0.6) -0.2 (-1.9–1.4) .856 .01 
 8’UG (secs) Δ B–12 -0.44 (±0.24) -0.25 (±0.21) -0.19 (-0.85–0.46) .555 .01 
 Δ B–24 -0.29 (±0.30) -0.32 (±0.26) 0.03 (-0.80–0.86) .943 .00 
 50’W (secs) Δ B–12 -0.31 (±0.23) -0.61 (±0.20) 0.30 (-0.32–0.91) .335 .03 
 Δ B–24 -0.23 (±0.25) -0.40 (±0.22) 0.17 (-0.50–0.85) .606 .08 
 VO2max (L/min) Δ B–12 0.0 (±0.0) 0.0 (±0.0) 0.0 (-0.1–0.1) .762 .00 
Δ B–24 0.0 (±0.1) +0.1 (±0.0) -0.1 (-0.2–0.1) .219 .06 
 
IKES = isometric knee extensor strength; HGS = handgrip strength; STS-30 = sit-to- stand in 30 second test; 8’UG = 8-foot up and go; 50’W = 50-foot walk; 
VO2max = estimated V02max from Siconolfi step test. Changes (Δ) between time points (B = baseline, 12 = week 12 (immediately post-supplementation); 24 = 
week 24 (12 weeks post-supplementation)) are presented as the adjusted mean (±SE) from ANCOVA. The between-group difference for each Δ is displayed 
with 95% confidence interval (CI) and effect size, eta squared (η2): small = .01; medium = .08; large = .26; very large = .50. * P < .05; # P = .05–.10.
Figure 1. CONSORT diagram showing recruitment and path of patients through 
the study 
 
GFR = (estimated) glomerular filtration rate; Cr = Creatine supplementation group; DNC = randomised 
but did not commence treatment (i.e. did not attend baseline and were subsequently withdrawn); * = 
due to missing data, final analysis for body composition data included values using Expectation-
Maximization imputed data; # = missed sessions (placebo) at day 6, week 12 and week 24 were not 
the same participant.  
 
